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SIGNIFICANCE
Methotrexate and biologics are the most-used systemic 
treatments for psoriasis. This study describes the beliefs 
(necessity to use, and concerns about these treatments) 
of patients using these treatments, and factors associated 
with these beliefs. Patients using biologics were found to 
have a higher necessity to use the treatment than those 
using methotrexate. A high necessity was associated with 
a low Psoriasis Area and Severity Index in both treatment 
groups, and with longer treatment duration in the metho-
trexate group. Most patients using biologics could be classi-
fied as “accepting” the treatment, and most patients using 
methotrexate as “indifferent” to the treatment. Identifying 
patients with a sceptical, ambivalent or indifferent profile 
could be useful, because these profiles could negatively in-
fluence patient’s attitude towards their medication.
Methotrexate (MTX) and biologics are frequently used 
treatments for psoriasis. Exploring patients’ beliefs 
about their treatment may help to elucidate patients’ 
attitudes towards these therapies. A cross-sectional 
survey was conducted using the Beliefs about Medici-
nes Questionnaire-Specific (BMQ-Specific) in patients 
treated with methotrexate or biologics. BMQ-Specific 
scores (Necessity and Concerns scales) were calcula-
ted and patients were classified as “accepting”, “in-
different”, “ambivalent” or “sceptical” towards their 
treat ment. Biologics users scored higher on the Neces-
sity scale than did methotrexate users. Both groups 
had lower Concerns scores than Necessity scores. A 
high Necessity scale was associated with a low Psoria-
sis Area and Severity Index score in both groups and 
long treatment duration in the methotrexate group. 
Although this study cannot make a direct comparison, 
it was observed that most patients on biologics could 
be classified as “accepting” (59%), and most patients 
on MTX could be classified as “indifferent” (47%). In 
conclusion, the BMQ-Specific is useful to identify pa-
tients with a sceptical, ambivalent or indifferent pro-
file. These profiles may negatively influence patient’s 
attitude towards their medication. 
Key words: psoriasis; beliefs about medicines; biologics; 
metho trexate; BMQ; cross-sectional.
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Psoriasis is a chronic, immune-mediated inflammatory skin disease, affecting 2–4% of the population in 
western countries (1). Moderate-to-severe psoriasis is 
usually treated with systemic therapies, such as metho-
trexate (MTX) or biologics. Since psoriasis is a chronic 
disease, patients need long-term treatment to control the 
disease. MTX is a well-known conventional systemic 
therapy for continuous treatment of moderate to severe 
plaque psoriasis; biologics are often the next step in the 
treatment when conventional systemic therapies fail or 
are contraindicated (2, 3). It is important that patients 
use these therapies adequately in order to obtain disease 
control. It is well-known that the attitudes of patients 
towards medicines, including adherence, are influenced 
by their beliefs about the prescribed medication (4–9). 
The Beliefs about Medicines Questionnaire Specific 
(BMQ-Specific) is the most-used tool to assess these 
beliefs, expressed as Necessity and Concerns scores, 
about the prescribed medication for a specific disease. 
The use of this questionnaire in other chronic diseases 
has shown that patients who perceive high Necessity and 
low Concerns towards their medication are more likely 
to use their treatment as recommended by the prescriber 
(4). Assessing the balance between patients’ Necessities 
and Concerns about their prescribed medication helps 
elucidate the attitude (positive or negative) of patients 
towards their medication (4, 10).
Because MTX and biologics are among the most im-
portant systemic treatments for psoriasis in daily clinical 
practice, it is crucial to explore the beliefs of patients 
regarding these treatments. In addition, identifying the 
factors that may affect these beliefs is important in order 
to search for specific interventions (e.g. counselling) to 
prevent treatment failure. The objective of this study 
was therefore to explore the beliefs about medicines in 
patients with psoriasis treated with MTX or biologics, 
using the BMQ-Specific questionnaire (10). In addition, 
this study sought determinants that were associated with 
either high Necessity or low Concerns scores. 
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METHODS
Study population
This cross-sectional survey was conducted between 6 January 2014 
and 23 June 2015 at the outpatient clinic of the Department of 
Dermatology, Radboud University Medical Center (Radboudumc) 
in Nijmegen, the Netherlands. Adult patients (> 18 years) with 
plaque psoriasis who were treated with MTX or biologics (either 
adalimumab, etanercept, infliximab or ustekinumab) for psoriasis, 
were asked at the time of consultation to complete the BMQ-
Specific. Consecutive patients visiting the outpatient clinic were 
asked to participate until 100 patients treated with MTX and 100 
patients treated with biologics were included. This study did not 
require approval from an institutional review board according to 
ethics guidelines in the Netherlands. 
Beliefs about Medicines Questionnaire-Specific
The BMQ-Specific is a validated instrument that assesses beliefs 
about medication (10). This instrument can be adapted to a specific 
treatment by adding the name of the medication investigated to the 
questionnaire. In the current study, the BMQ-Specific was adapted 
to patients with psoriasis, with reference to their specific treatment 
for psoriasis being MTX, adalimumab, etanercept, infliximab or 
ustekinumab. Patients treated with a combination of systemic anti-
psoriatic therapies were asked to answer the questionnaire only 
for their main treatment, which was a biologic in case of biologic 
combined with another systemic treatment. 
The BMQ-Specific consists of 2 5-item scales assessing Neces-
sity and Concerns regarding the prescribed medication. An ex-
ample of a Necessity item is: “Without this medication, I would be 
very ill”, and an example of a Concerns item is: “These medicines 
disrupt my life”. Each item is measured on a 5-point Likert scale, 
ranging from “strongly disagree” (=1) to “strongly agree” (=5), 
with “uncertain” in the middle. The sum of the scores of the indi-
vidual items of the Necessity scale and Concerns scale for MTX 
and biologics was used to calculate each scale score. The scales 
scores range from 5 to 25. A higher score on the Necessity scale 
reveals stronger beliefs in the necessity of that particular medica-
tion, while a higher score on the Concerns scale indicates stronger 
concerns about that particular medication (4, 10). In addition, the 
Necessity and Concern scales were split at the midpoint (15 points) 
to create 4 “attitude subgroups”: accepting (high Necessity and 
low Concerns), ambivalent (high Necessity and high Concerns), 
indifferent (low Necessity and low Concerns), and sceptical (low 
Necessity and high Concerns) (11).
A Necessity–Concerns Differential (NCD) was calculated by 
subtracting the Concerns scores of each patient from their Neces-
sity scores. This differential results in a score ranging from – 20 to 
+20. Higher scores on this differential indicate higher perceived 
necessity than concerns. See Appendix S11 for the BMQ-Specific. 
Patient general characteristics
Demographic and clinical characteristics were extracted from 
electronic medical records. For this study, the following data were 
extracted: age, sex, age at onset of psoriasis, the PASI score at the 
time of the survey, diagnosis of psoriatic arthritis (PsA) (yes/no), 
disease duration at time of survey, age at start of MTX or biologic 
treatment, and history of systemic therapies and phototherapy for 
psoriasis prior to the investigated drug. 
Data analysis
Results were reported as follows: continuous parametric variables 
as means with standard deviations (SDs), continuous non-para-
metric variables as medians with ranges, and categorical variables 
as percentages. This accounts for the scores of the Necessity and 
Concerns scales, the NCD and baseline parameters. The indivi-
dual item scores were categorized into 3 categories: scores below 
3 were categorized as “disagreement”, scores equal to 3 were 
categorized as “uncertain”, and scores above 3 were categorized 
as “agreement”. To avoid a judgment on the answer “uncertain”, 
because it is unknown what it meant to the patient, it was decided 
to score this answer separately. The proportions of patients per 
category were analysed. 
Univariable linear regression analysis was performed to evaluate 
the possible association between the Necessity scale, Concerns 
scale or NCD, with general patient and treatment characteristics 
for the MTX and for the biologics group separately. Variables 
with a p-value < 0.2 in univariable analysis were analysed further 
using multivariable linear regression analysis with backward se-
lection to assess which variables were independently associated 
with the Necessities or Concerns scales and NCD. Inclusion of 
candidate predictors in the regression model was set at a cut-off 
point of p < 0.2 in univariate testing. This is rule of thumb to se-
lect candidate predictors with potential predictive value without 
being too strict.
Due to the observational nature of this study, no formal statistical 
comparison between the MTX and biologic group was presented, 
because the groups were different in multiple, essential, confoun-
ding aspects which it was not possible to correct for.
Analyses were performed with SPSS version 20.0 (SPSS, Inc., 
Chicago, IL, USA). A p-value ≤ 0.05 was considered statistically 
significant.
1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3108
Table I. General characteristics of patients
MTX 
n = 100
Biologics
n = 100
p- 
value
Age, years, mean ± SD 53.3 ± 13.6 51.3 ± 13.2 0.31
Male sex, n (%) 56 (56) 68 (68) 0.08
Age at onset of psoriasis, years, median 
(range)
24 (6–66) 22 (1–61) 0.37
PASI at the time of the survey, median 
(range)
4.9 (0–32.3) 3.1 (0–16.2) 0.001
Diagnosis of psoriatic arthritis, yes, n (%) 14 (14) 24 (24) 0.07
Disease duration at the time of the 
survey, years, mean ± SD
25.5 ± 13.8 26 ± 12.8 0.76
Age at start treatment, years, mean ± SD 48.5 ± 12.5 48.2 ± 13.2 0.9
Treatment duration, years, median 
(range)
2.6 (0.07–37) 2.8 (0.06–10.3) 0.6
History of psoriasis therapiesa
Number of conventional systemic therapiesb
0 40 (40)   2 (2) 0.001
1 40 (40)   9 (9)
2 14 (14) 34 (34)
3   4 (4) 42 (42)
4   2 (2) 13 (13)
Number of biologic therapiesc
0 90 (90) 38 (38) 0.001
1   6 (6) 31 (31)
2   3 (3) 19 (19)
3   1 (1) 10 (10)
4   0   2 (2)
Phototherapy
Yes 77 (77) 96 (96) 0.001
No 23 (23)   4 (4)
aTherapies are counted only once per patient, regardless of the number of times they 
are prescribed. bConventional systemic therapies: acitretin, cyclosporine, fumarates 
or methotrexate (MTX); cbiologic therapies: adalimumab, alefacept, etanercept, 
infliximab  or ustekinumab. All data were included. No missing values were found. 
PASI: Psoriasis Area and Severity Index; SD: standard deviation. Significant 
p-values (p < 0.05) are shown in bold.
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RESULTS
All invited patients agreed to participated and completed 
the questionnaire (response rate 100%). A total of 200 
patients completed the BMQ-Specific questionnaire. 
One hundred patients were treated with MTX and 100 
with biologics (adalimumab, n = 35; etanercept, n = 31; 
infliximab, n = 7; ustekinumab, n = 27). Table I shows the 
characteristics of the MTX and biologic groups.
In the MTX group, 2 patients were treated with MTX 
in combination with other conventional systemic therapy 
(one patient started cyclosporine and MTX at the same 
time, due to the severity of the psoriasis at that time, 
and the other one started fumarates during the MTX 
treatment due to insufficient efficacy of MTX). In the 
biologic group, 15 (15%) patients received combination 
systemic therapy at the time of the survey (14 patients 
were treated with biologics in combination with MTX 
(adalimumab, n = 6; etanercept, n = 3; infliximab, n = 2, 
and ustekinumab, n = 3) and one patient was treated with 
ustekinumab in combination with acitretin).
Significant differences were found between the MTX 
and biologic groups for the baseline PASI score, the 
number of previous systemic therapies for psoriasis 
(conventional and biologics) and phototherapy (p = 0.05). 
The differences in patient and treatment characteristics 
split between 3 main biologic treatments in the study 
(adalimumab, etanercept and ustekinumab), are shown 
in Appendix S21. 
Beliefs about Medicines Questionnaire scores
Patients treated with biologics scored higher than MTX 
patients on all items of the Necessity scale, as shown in 
Table II. The highest scores in both treatment groups 
were found for the item “My psoriasis medication 
protects me from becoming worse” (MTX = 65% vs. 
biologics = 72%), followed by “My life would be impos-
sible without my psoriasis medication” (MTX = 46% vs. 
biologics = 71%). Furthermore, in the biologics group, 
62% of the patients believed that their present health 
depended on their psoriasis medication (reference: 42% 
in the MTX group) and 58% believed that their health 
in the future will depend on their psoriasis medication 
(reference: 35% in the MTX group).
In both treatment groups, most patients reported no 
concerns on all items, except for the item “I sometimes 
worry about the long-term effects of my psoriasis medi-
cation” where 49% of the MTX patients and 41% of the 
biologic patients reported concerns. 
Tables III and IV summarize the mean and 95% 
confidence interval (95% CI) of the Necessity scale, 
Concerns scale and the NCD scores for the MTX and 
biologic groups in general and stratified for treatment 
duration and PASI scores. Fig. 1 shows the mean and 
the standard deviations (SD) of the BMQ-Specific scores 
split for MTX and biologics.
Patients treated for more than 1 year with MTX 
reported higher Necessity (p = 0.04) for the treatment 
Table II. Percentage of Beliefs about Medicines Questionnaire Specific (BMQ)-Specific scores per treatment group
Necessity scale MTX (%) Biologics (%) Concerns scale MTX (%) Biologics (%)
Necessity 1
My health at present depends on my psoriasis 
medication
< 3 38 25 Concerns 1
Having to take my psoriasis medication 
worries me
< 3 54 69
3 20 13 3 13 10
> 3 42 62 > 3 33 21
Necessity 2
My life would be impossible without my 
psoriasis medication
< 3 27 16 Concerns 2
I sometimes worry about the long term 
effects of my psoriasis medication
< 3 36 41
   3 27 13    3 15 18
> 3 46 71 > 3 49 41
Necessity 3a
Without my psoriasis medication I would be 
very ill
< 3 60 36 Concerns 3
My psoriasis medication is mystery to me
< 3 70 71
   3 18 18    3 13 17
> 3 21 45 > 3 17 12
Necessity 4
My health in the future will depend on my 
psoriasis medication
< 3 40 18 Concerns 4a 
My psoriasis medication disrupt my life
< 3 81 86
   3 25 24    3 8 7
> 3 35 58 > 3 10 6
Necessity 5b
My psoriasis medication protects me from 
becoming worse
< 3 17 15 Concerns 5
I sometimes worry about becoming too 
dependent on my psoriasis medication
< 3 80 54
   3 18 12    3 21 21
> 3 65 72 > 3 20 25
aOne missing value in the methotrexate (MTX) and biologics groups; b1 missing value in the biologic group. Necessity and Concerns scales were divided into 3 parts: 
< 3 (score 1–2)=disagreement; 3=uncertain; >3 (score 4–5)=agreement.
Table III. Beliefs about Medicines Questionnaire (BMQ)-Specific scale and Necessity–Concerns Differential (NCD) scores for methotrexate 
and biologics
BMQ-Specific
Methotrexate
Total
(n = 100)
Biologics
Total 
(n = 100)
Adalimumab
(n = 35)
Etanercept
(n = 31)
Ustekinumab 
(n = 27)
Necessitya, mean ± SD [CI] 15.3 ± 4.6 [14.4–16.2] 18 ± 4.4 [17.1–18.9] 17.8 ± 4.4 [16.3–19.3] 19 ± 4.2 [17.5–20.5] 17.7 ± 4.4 [15.9–19.4]
Concernsa, mean ± SD [CI] 12.3 ± 4.1 [11.5–13.1] 11.7 ± 3.5 [11–12.4] 11.4 ± 3.2 [10.3–12.5] 11.6 ± 4.1 [10.1–13.1] 11.9 ± 3.3 [10.5–13.2]
NCDb, mean ± SD [CI]   2.98 ± 5.9 [1.82–4.14]   6.3 ± 5.6 [5.2–7.4)   6.4 ± 5.4 [4.6–8.3]   7.4 ± 5.5 [5.4–9.4]   5.8 ± 5.4 [3.7–7.9]
aScores range from 5 to 25. bScores range from –20 to 20. SD: standard deviation; CI: confidence interval.
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than patients treated for less than 1 year (15.9 ± 4.4 and 
13.8 ± 5, respectively). In the biologic group, patients with 
a PASI score ≤ 5 reported higher Necessity (p = 0.007) for 
the treatment than patients with a PASI score greater than 
5 (18.7 ± 4.3 and 16 ± 4.4, respectively). Dividing the pa-
tients into 4 attitude subgroups showed that, in the MTX 
group, 29% of the patients could be categorized as ac-
cepting, 12% as ambivalent, 47% as indifferent, and 12% 
as sceptical. In the biologic group, 59% of patients could 
be categorized as accepting, 10% as ambivalent, 28% 
as indifferent, and 3% as sceptical (Fig. 2). The NCD 
resulted in a positive score for both treatment groups. 
This indicates a stronger belief in the necessity of MTX 
or biologics treatment than in the concerns about taking 
these medications (3.0 ± 5.9 and 6.3 ± 5.6, respectively). 
In addition, statistically significant differences (p = 0.003) 
were found for the NCD split for the PASI score in the 
biologic group (7.2 ± 5.1 and 3.5 ± 6, respectively).
Factors associated with the beliefs about medication 
MTX group. Univariable analyses showed that age, 
sex, age at onset of psoriasis, PASI score at the time of 
the survey and MTX treatment duration were possibly 
associated with the Necessity scale in the MTX group 
when selecting those with a p-value below 0.2. The 
factor possibly associated with the Concerns scale was 
the number of previous systemic conventional therapies. 
The factors possibly associated with the NCD were: age 
at onset of psoriasis, height of the PASI score at the time 
of the survey and MTX treatment duration (all p-values 
< 0.2) (see Appendix S31 for more information on the 
univariable analyses).
Those variables identified in the univariable analyses 
were included in the multivariable regression analysis. 
This revealed that in the MTX group the PASI score 
(beta –0.246, 95% CI (–0.437;–0.055); p = 0.012) and the 
treatment duration (beta 0.180, 95% CI (0.042; 0.318); 
p = 0.011) were associated with the Necessity scale. This 
means that the higher the PASI score at the time of the 
survey, the lower the Necessity score for MTX treatment: 
and the longer the MTX treatment duration, the higher 
the Necessity score for MTX treatment. For the Concerns 
score, only one factor, namely “history of conventional 
therapies”, could be selected based on the p-value of 0.2 
in the univariable analyses; however, that variable did 
not reach statistical significance (p = 0.08).
Regarding the NCD, also the PASI score (beta –0.249, 
95% CI (–0.497; –0.002); p = 0.05) and the MTX treat-
ment duration (beta 0.195, 95% CI (0.017; 0.374); 
p = 0.032) were found to be associated with the NCD.
Biologic group. Based on the univariable analysis, the 
factors possibly associated with the Necessity scale in 
the biologic group were: the PASI at the time of the 
Table IV. Beliefs about Medicines Questionnaire (BMQ)-Specific scale and Necessity-Concerns Differential (NCD) stratified by treatment 
duration and Psoriasis Area and Severity Index (PASI) scores
BMQ-Specific
Methotrexate (n = 100) Biologics (n = 100)
Total 
(n = 100)
Treatment duration
p-value
Total 
(n = 100)
Treatment duration
p-value
≤ 1 year 
(n = 28)
> 1 year 
(n = 72)
≤ 1 year 
(n = 25)
> 1 year 
(n = 75)
Necessitya, mean ± SD [CI]
15.3 ± 4.6
[14.4–16.2]
13.8 ± 5
[11.9–15.7]
15.9 ± 4.4
[14.9–16.9] 0.04
18 ± 4.4
[17.1–18.9]
16.7 ± 4.5
[14.8–18.5]
18.4 ± 4.3
[17.4–19.4] 0.09
Concernsa, mean ± SD [CI]
12.3 ± 4.1
[11.5–13.1]
12.1 ± 3.7
[10.7–13.6]
12.4 ± 4.2
[11.4–13.4] 0.74
11.7 ± 3.5
[11–12.4]
12 ± 3.4
[10.6–13.5]
11.6 ± 3.5
[10.8–12.4] 0.58
NCDb, mean ± SD [CI]
2.98 ± 5.9
[1.82–4.14]
1.7 ± 5.7
[–0.54–3.9]
3.5 ± 5.9
[2.1–4.9] 0.17
6.3 ± 5.6
[5.2–7.4)
4.6 ± 6.9
[1.8–7.5)
6.9 ± 5
[5.7–8) 0.09
PASI ≤ 5 PASI > 5 PASI ≤ 5 PASI > 5
Necessitya, mean ± SD [CI]
15.3 ± 4.6
[14.4–16.2]
15.7 ± 4.9
[14.3–17]
14.9 ± 4.4
[13.6–16.2] 0.42
18 ± 4.4
[17.1–18.9]
18.7 ± 4.3
[17.7–19.7]
16 ± 4.4
[14.2–17.8] 0.007
Concernsa, mean ± SD [CI]
12.3 ± 4.1
[11.5–13.1]
12.3 ± 4.1
[11.1–13.4]
12.4 ± 4.1
[11.2–13.6] 0.89
11.7 ± 3.5
[11–12.4]
11.5 ± 3.3
[10.7–12.2]
12.4 ± 4
[10.8–14.1] 0.221
NCDb, mean ± SD [CI]
2.98 ± 5.9 
[1.82–4.14]
3.4 ± 6.6 
[1.6–5.2]
2.5 ± 5
[1.1–4] 0.46
6.3 ± 5.6 
[5.2–7.4)
7.2 ± 5.1
[6.1–8.4)
3.5 ± 6
[1–6) 0.003
aScores range from 5 to 25. bScores range from –20 to 20. Significant p-values (p < 0.05) are shown in bold. SD: standard deviation; CI: confidence interval.
Fig. 1. Beliefs about Medicines Questionnaire Specific (BMQ-Specific) 
scores split for methotrexate (MTX) and biologics. Means with standard 
deviations of the BMQ-Specific scores split for MTX and biologics are 
depicted in this figure. Biol: biologics NCD: Necessity-Concerns Differential.
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survey and the number of previous biologic therapies. 
The factors possibly associated with the Concerns scale 
were: sex, diagnosis of PsA and the number of previous 
conventional therapies. The factors possibly associated 
with the NCD were: PASI score at the time of the sur-
vey and diagnosis of PsA (all p-values < 0.2). Again, 
the variables selected in this first step were included in 
the multivariable regression analysis. This revealed that 
the PASI score (beta –0.343, 95% CI (–0.598; 0.087); 
p = 0.01) was associated with the Necessity scale. This 
means, the higher the PASI score at the time of the survey 
the lower the necessity of the patients for the biologic 
treatment. None of the possible factors associated with 
Concerns for the biologic group in the univariable ana-
lysis reached statistical significance in the multivariable 
analysis. Furthermore, the PASI score (beta –0.420, 95% 
CI (–0.741; –0.099); p = 0.011) and the diagnosis of PsA 
were found to be associated with the NCD (beta 2.606, 
95% CI (0.097–5.116); p = 0.042). This means that the 
presence of PsA at the time of the survey was associated 
with an increase in the belief of the patients about the 
necessity of the biologic treatment compared with the 
absence of PsA.
Table V shows a summary of the results of the multi-
variable regression analysis.
DISCUSSION
This study found that most patients treated with MTX 
or biologics have a positive balance between Necessity 
and Concerns regarding their MTX or biologic treatment. 
In other words, the patients treated with MTX or bio-
logics often reported more necessity for the prescribed 
medication to control their disease than concerns about 
taking these drugs. However, most of the patients treated 
with biologics could be classified as “accepting”, while 
most patients in the MTX group could be classified as 
“indifferent”.
In the Necessity scale, both treatment groups scored 
highest for the item “My psoriasis medication protects 
me from becoming worse”, followed by “My life would 
be impossible without my psoriasis medication” and “My 
health at the present depends on my psoriasis medica-
tion”. This indicates that patients acknowledge the need 
for medication to control their disease. With regards to 
the Concerns Scale, the item “I sometimes worry about 
the long-term effects of my psoriasis medication” was 
most often scored positively (40% of patients).
The high scores on the Necessity scale in the bio-
logic group could be explained by the long history of 
psoriasis therapies previous to the biologic treatment. 
This probably means that they have failed to respond 
to many other therapies, which can result in feelings of 
dependency on biologic therapy as a last resort. These 
feelings could be reinforced by the fact that in the most 
European countries, biologic therapy can only be pres-
cribed by failure or contraindication of conventional 
systemic therapies. Higher Necessity scores in patients 
treated with biologics than in those treated with conven-
tional systemic therapies were also reported in the study 
Fig. 2. Classification of patients in 4 attitudes subgroups on the basis of their Necessity and Concerns (methotrexate (MTX) n = 100; biologics 
n = 100).
Table V. Summary of backward stepwise multivariable regression analysis for methotrexate (MTX) and biologics
Treatment Factors
BMQ-Specific Necessity scale Necessity–Concerns Differential
Beta 95% CI p-value Beta 95% CI p-value
MTX Psoriasis Area and Severity Index –0.246 [–0.437, –0.055] 0.012 –0.249 [–0.497, –0.002] 0.048
Treatment duration (years)   0.180 [0.042, 0.318] 0.011   0.195 [0.017, 0.374] 0.032
Biologics Psoriasis Area and Severity Index –0.343 [–0.598, –0.087] 0.009 –0.420 [–0.741, –0.099] 0.011
Diagnosis of psoriatic arthritis   2.606 [0.097–5.116] 0.042
A p-value < 0.05 was considered statistical significant. None of the factors associated with Concerns for the MTX or biologic group reached statistical significance (p < 0.05).
BMQ-Specific: Beliefs about Medicines Questionnaire Specific; CI: confidence interval.
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of Michetti et al. (12) To our knowledge, the study of 
Michetti et al. is the only study that has investigated the 
BMQ-Specific questionnaire in patients with psoriasis. 
They focused on conventional therapies in general and 
on tumour necrosis factor inhibitors treatments (TNFi). 
The current study focused specifically on MTX as the 
most-used conventional treatment, and was not limited 
to TNFi treatments, but also included interleukin 12/23 
treatment (ustekinumab). In addition, the study presented 
factors that might influence beliefs about medicine in 
patients with psoriasis.
Multivariable regression analyses revealed factors both 
positively and negatively associated with the Necessity 
scale and with the NCD. Longer MTX treatment duration 
was positively associated with higher Necessity for MTX 
treatment and with a positive NCD. Correspondingly, 
patients treated > 1 year reported higher Necessity for 
MTX than patients treated < 1 year. As an explanation, 
we hypothesized that patients will remain on MTX as 
long as their disease remains controlled, thus they expe-
rience high necessity. Another positive factor associated 
with the NCD, was the diagnosis of PsA in the biologic 
group. In the current study, the frequency of PsA in 
biologic patients was higher than PsA in MTX-treated 
patients. This could be explained by the fact that biologic 
treatments are prescribed when PsA does not respond to 
systemic conventional treatments. This might be likely 
to increase the necessity of these patients to receive a 
biologic treatment to control their arthritis and their skin 
disease. A negative factor associated with the Necessity 
scale and the NCD, in the MTX as well as the biologic 
groups, was a high PASI score. Correspondingly, patients 
with a low disease severity (PASI score ≤ 5) reported 
higher Necessity scores than patients with more disease 
activity. This could mean that when patients experience 
less effect of their medication, they experience less ne-
cessity for that treatment. 
Study strengths and limitations
These results should be interpreted in the light of some 
limitations. First, we decided not to perform formal statis-
tical comparisons between the MTX and biologic groups, 
because the groups were different in multiple, essential, 
aspects that are an inherent bias in non-randomized 
studies. Secondly, due to the nature of the current study 
design, it was not possible to measure the number and 
severity of adverse events experienced by the partici-
pants associated with current or previous treatments. 
Therefore, these adverse events were not included as 
candidate predictors in the current study. Participants’ 
experiences with adverse events could hypothetically 
lead to more concerns about treatments. However, our 
results showed no statistically significant differences 
in Concerns between the participants treated for less or 
more than one year in both treatment groups. Thirdly, 
at the time we were analysing our data, Thorneloe et al. 
(13), suggested that some patients with psoriasis might 
experience difficulties completing the BMQ and that 
medication beliefs were underestimated or not fully 
captured in the BMQ items. However, that study was 
based on a small number of patients recruited from a 
non-clinical setting, who might interpret items differently 
from a clinical population under systemic treatment, as 
in the current study. In addition, the external validity 
of the study may be influenced by socioeconomic and 
demographic characteristics, which might be different 
in other populations. 
A strength of the current study is the 100% response 
rate. Therefore, the generalizability of the study is not 
limited by volunteer bias. 
Conclusion
It is quite reassuring that patients expressed more neces-
sity than concerns. However, not all patients could be 
classified as “accepting” with regards to their medication. 
Non-accepting profiles, such as sceptical, indifferent or 
ambivalent ones, could negatively influence a patient’s 
attitude towards the use of prescribed medicines. Mea-
suring the BMQ-Specific in daily practice could reveal 
an individual patient profile that should be taken into 
account during counselling. For example, sceptical or 
ambivalent patients experience high levels of concerns 
about their medication use and might be helped by 
more information about a realistic risk profile of their 
medication. At least these patients should be monitored 
on therapy adherence because they could be prone to 
non-adherent behaviour.
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